Intravenous Magnesium in Patients Receiving Cisplatin

Feasibility and acceptability as measured by participant rates of enrollment [ Time Frame: 6 months ]
Feasibility assessed by % of patients that agree to participate. Project feasible if >30% of the patients approached agree to participate
Number of Participants With Treatment-Related Adverse Events as Assessed by CTCAE Version 5.0 [ Time Frame: Time of magnesium infusion till 2 days. ]
NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

Magnesium Level [ Time Frame: Day of surgery through postoperative day 3. ]
Assess the amount of IV magnesium needed to reach a target level of 3 to 4.8mg/dl. Magnesium levels will be measured at multiple time points. We want >80% (≥32/40) of the time-averaged, postoperative magnesium levels to be within the target range of 3 to 4.8 mg/dl.
Tubular Injury Markers [ Time Frame: From admission through postoperative day 3 ]
Changes in urinary KIM-1 and urinary NGAL levels in order to assess intra- and interassay variability

Adults ≥18 years with malignant mesothelioma admitted for HIOCC. Because no dosing or adverse event data are currently available on the use of intravenous magnesium participants <18 years of age, children are excluded from this study, but will be eligible for future pediatric studies.
Glomerular filtration rate (GFR)≥ 30 ml/min/1.73m2 at the time of enrollment
Patients must have the ability to understand and the willingness to sign a written informed consent document.

Patients with a pre-treatment serum Magnesium level >3 mg/dl at the preoperative visit
Patients with AKI at the time of enrollment, assessed by Kidney Disease Improving Outcomes Criteria (serum creatinine increase ≥1.5x baseline)
Patients with estimated glomerular filtration rate <30 ml/min/1.73m2 at the time of enrollment
Patients with neuromuscular disease (e.g., amyotrophic lateral sclerosis, multiple sclerosis, muscular dystrophy, myasthenia gravis, myositis)
Patients with sustained bradycardia (heart rate <50 beats per minute on 1 or more EKGs in the preceding 90 days) or 2nd degree AV heart block type 2 or higher with the absence of a functioning pacemaker
Participants who are receiving any other investigational agents.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to intravenous magnesium
Participants with uncontrolled intercurrent illness.
Participants with psychiatric illness/social situations that would limit compliance with study requirements.
Pregnant women are excluded from this study because they may need magnesium for treatment of preeclampsia or eclampsia, apart from this study.

From the blog